Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 993Neoplasms 852Carcinoma, Non-Small-Cell Lung 845Prostatic Neoplasms 528Neoplasm Metastasis 501Leukemia, Myeloid, Acute 489Melanoma 456Colorectal Neoplasms 447Multiple Myeloma 441Lung Neoplasms 422Pancreatic Neoplasms 353Recurrence 350Lymphoma 350Ovarian Neoplasms 341Lymphoma, Non-Hodgkin 329Leukemia 324Leukemia, Lymphocytic, Chronic, B-Cell 302Precursor Cell Lymphoblastic Leukemia-Lymphoma 271Carcinoma, Renal Cell 256Head and Neck Neoplasms 246Brain Neoplasms 245Carcinoma, Hepatocellular 234Glioblastoma 232Squamous Cell Carcinoma of Head and Neck 231Myelodysplastic Syndromes 231Lymphoma, Large B-Cell, Diffuse 228Lymphoma, Follicular 219Colonic Neoplasms 191Stomach Neoplasms 182Rectal Neoplasms 175

Interventions

Cannabidiol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Interventional × Tuberous Sclerosis 2 × Clear all
NCT04485104 2025-10-31

Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures

Jazz Pharmaceuticals

Phase 3 Terminated
3 enrolled 28 charts

Tuberous Sclerosis 1, Tuberous Sclerosis 2, Epilepsy, Epilepsies, Myoclonic, Seizures, Spasms, Infantile, Tuberous Sclerosis, Lennox Gastaut Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡